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WHAT THIS PAPER ADDS?
 This study shows how some complications of endovenous laser ablation can be avoided. It can inﬂuence the use of endovenous laser
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Objective: This clinical trial aimed to evaluate the clinical results of the use of a tulip ﬁbre versus the use
of a bare ﬁbre for endovenous laser ablation.
Methods: In a multicentre prospective randomised trial 174 patients were randomised for the treatment
of great saphenous vein reﬂux. A duplex scan was scheduled 1 month, 6 months and 1 year
postoperatively.
Ecchymosis was measured on the 5th postoperative day. In addition, pain, analgesics requirement,
postoperative quality of life (CIVIQ 2) and patient satisfaction rate were noted.
Results: Patients treated with a tulip ﬁbre had signiﬁcantly less postoperative ecchymosis (0.04 vs. 0.21;
p < 0.001) and pain (5th day) (1.00 vs. 2.00; p < 0.001) and had a better postoperative quality of life (27
vs. 32; p ¼ 0.023). There was no difference in analgesic intake (p ¼ 0.11) and patient satisfaction rate
(p ¼ 0.564). The total occlusion rate at 1 year was 97.02% and there was no signiﬁcant difference between
the two groups (p ¼ 0.309).
Conclusion: Using a tulip ﬁbre for EVLA of the great saphenous vein results, when compared with the use
of a bare ﬁbre, in equal occlusion rates at 1 year but causes less postoperative ecchymosis and pain and in
a better postoperative quality of life.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Purpose
In this multicentre randomised prospective trial, we wished to
evaluate the clinical use of a new safety ﬁbre tip,1 the tulip ﬁbre.
Can the use of this safety ﬁbre tip avoid some of the imperfec-
tions of endovenous laser ablation (EVLA)? In this clinical trial, two
patient groups were compared: one in which a bare ﬁbre was used
and a second one using the tulip ﬁbre. Primary outcome factors are
the possible side effects of the treatment: the amount of used
analgesics, postoperative pain, the appearance of postoperativeþ32 51425061.
ylsteke).
ciety for Vascular Surgery. Publisheecchymosis, patient satisfaction rate and a postoperative quality-
of-life (QoL) score (CIVIQ 2). Secondary outcomes were the occlu-
sion rates at 1 month, 6 months and 1 year postoperatively.
Introduction
Endovenous laser ablation (EVLA) has been introduced as
a minimally invasive alternative to ‘stripping’ in the treatment of
saphenous vein reﬂux. Different laser wavelengths are available.
This treatment results in a substantially lower morbidity, shorter
periods of sick leave and less postoperative pain as compared with
a classical stripping.2e7 Nevertheless, certain problems such as
postoperative ecchymosis, bruising and pain jeopardise the
recovery.d by Elsevier Ltd. All rights reserved.
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effects: the bare ﬁbre used for EVLA is a rigid ﬁbre. When this ﬁbre
is introduced in a saphenous vein, which usually has bends and
areas of tortuosity, the ﬁbre always has a tendency to straighten. As
a consequence of this straightening, and since the vein is more
compliant than the ﬁbre, the ﬁbre tip frequently hits the vessel
wall.8 Examining the ﬁbre location on perioperative ultrasound
control, we can see that the ﬁbre tip is most frequently situated in
a very eccentric position within the vein, with the tip touching the
vein wall.
Tumescent anaesthesia induces compression of the vein around
the ﬁbre and can alleviate the tendency towards an eccentric
position of the ﬁbre tip.
Even then, however, particularly in larger veins, the ﬁbre tip
remains in an eccentric position. In this situation when the energy
is delivered to the ﬁbre tip, direct contact between the ﬁbre tip and
the vessel wall results in a destruction and ulceration or perfora-
tion of the vein9,10; other parts of the vein wall are unaffected.1,9,10
The resulting uneven application of energy may be the cause of
some of the complications of EVLA, such as postoperative ecchy-
mosis, inﬂammation around the treated vein (periphlebitis) and
pain.11 A histological study showed that avoiding the direct contact
between the ﬁbre tip and the vein wall, and centring the ﬁbre tip
intraluminally, results in a more homogeneous vein wall destruc-
tion, fewer vein wall perforations and less perivenous tissue
destruction.1 The purpose of this clinical trial is to see whether
the use of this tulip ﬁbre may possibly result in fewer side effects
after EVLA.
Materials and Methods
Patient group
Between March 2010 and January 2011, 174 patients with
a unilateral great saphenous vein (GSV) incompetence were treated
in two hospitals: Sint-Andriesziekenhuis Tielt and the University
Hospital Gasthuisberg Leuven, Belgium.
Patients who met the inclusion criteria had insufﬁciency of the
GSV with functional and/or aesthetic inconvenience. In all patients,
the diagnosis of venous insufﬁciency was made by clinical evalu-
ation and Duplex studies. Only unilateral treatments were included.
Patients with concomitant insufﬁciency of the short (SSV) and/or
anterior saphenous vein (ASV) were excluded.
Other reasons for exclusion were deep venous insufﬁciency,
patients with a venous diameter exceeding 15 mm and cross-
dilatation with two or more incompetent side-branches, ther-
apeutical anticoagulation or hypocoagulopathy, hypercoagulopathy
or thrombophilia, occlusive peripheral arterial disease (ankle-
brachial pressure index <0.85) and pregnancy. All included
patients were a minimum age of 18 years.
Approval was obtained from the ethics committee of the
University Hospitals Leuven and the local research committee of
the Sint-Andries hospital (Tielt) and the research was carried
out according to the guidelines set out in the Declaration of
Helsinki.
A total of 215 patients met the inclusion and exclusion criteria
and 174 of them were randomised after signing an informed
consent form (Fig. 1, Consort ﬂow chart). Eighty-seven patients
were treated using a tulip ﬁbre, while the remaining 87 were
treated with a bare ﬁbre. We used a 1470-nm diode laser (Inter-
Medic, Barcelona, Spain and Quanta Systems, Olona Solvate
Italy). Randomisation was done using numbered and sealed
envelopes.
The patients were classiﬁed using the CEAP clinical classiﬁcation
(clinical, etiology, anatomy, pathophysiology).Description of the tulip ﬁbre
This safety ﬁbre1 consists of a bare ﬁbre with a hollow tube,
ﬁxed at the distal end of the ﬁbre. This tube has tulip-shaped, self-
expandable blades at its distal end (around the ﬁbre). The tube is
folded into an outer guiding catheter, which permits easy access to
the vein undergoing treatment. When the outer guiding catheter is
withdrawn (pullback), the tulip-shaped blades at the distal end of
this tube expand and push away the vein wall (Fig. 2). This
expansion centres the ﬁbre-tip intraluminal and thus avoids the
direct contact between the ﬁbre tip and the vein wall. It also
prevents pushing the ﬁbre further intraluminally into the deep
system.
The tube is made of stainless steel, which has excellent
mechanical and chemical resistance to high temperatures.
Technique
Prior to surgery, detailed duplex ultrasound mapping and
grading of the superﬁcial, deep venous and perforator systems was
performed in the standing position, including measurement of the
diameter of the incompetent saphenous vein at three reference
points (2 cm distal to the saphon-femoral junction (SFJ), mid-thigh
and knee). From these measurements, we calculated the average
diameter of the vein. The incompetent tributaries and perforating
veins were marked on the skin.
Access to the GSV was obtained by puncture under ultrasound
guidance, at the most distal reﬂux site. The laser ﬁbre was posi-
tioned 1.5 cm distal to the SFJ. Its position was veriﬁed by peri-
operative ultrasound and by visualisation of the red aiming beam
through the skin, which disappears on entering the common
femoral vein. Prior to laser ablation, a large quantity of tumescent
anaesthetic (40 ml Lidocaine 1% diluted with 500 ml Na HCO3 1.4%)
was injected around the GSV, under ultrasound control. At least
300 ml of ﬂuid was injected around the target vein.
The majority of patients (n ¼ 108) were treated with single local
tumescent anaesthesia. The remaining patients received additional
general (n ¼ 65) or spinal (n ¼ 1) anaesthesia.
All patients were treated in the Trendelenburg position and
perioperative manual compression was avoided since such
compression facilitates direct contact between the ﬁbre tip and the
vein wall, thus increasing the risk of perforation.
All GSV ablations were accompanied by a Muller phlebectomy.
Phlebectomies were not performed in the immediate vicinity of the
treated GSV, in order not to interfere with the measurement of
ecchymosis resulting from the EVLA.
Postoperative care and follow-up
Compression stockings (class 2) were applied for 3 weeks
postoperatively. All patients were treated in an outpatient setting
and were encouraged to return to normal activities as soon as
possible. A prescription for Diclofenac 75 was given on discharge
with the instructions only to take them if they became aware of
pain or inﬂammation in the treated leg and then to take two
capsules daily. Only patients at risk (history of deep venous
thrombosis (DVT) or superﬁcial thrombophlebitis, obesity body
mass index (BMI) > 35) received DVT prophylaxis in the form of
low-molecular-weight heparin (Enoxaparine 40 mg) for 10 days
(thrombophilia was an exclusion criterion).
Clinical follow-up appointments were scheduled at 5 days, 1
month, 6 months and 1 year postoperatively. Several clinical scores
were used: level of analgesic intake, a visual analogue pain score
(VAS), a postoperative QoL score, an ecchymosis score and the
patient satisfaction rate.
Assessed for treatment (n=368)  insufficient GSV (inclusion criteria) 
Fulfilled inclusion and exclusion criteria 
(n=215)
Excluded (n=153):  
bilateral treatment 
incompetence SSV/ASV 
Diameter>15mm 
Deep insufficiency 
Hypocoagulopathy/Hypercoagulopathy 
Occlusive arterial disease 
Pregnancy 
<18years old 
Refused randomisation (n=41)
Randomised (n=174)
Allocated for EVLA using a Tulip fibre 
(n=87)
Allocated for EVLA using a bare fibre 
(n=87)
Analysed with a follow-up of 1 month (n=87) Analysed with a follow-up of 1 month (n=87)
Analysed with a follow-up of 6 months (n=83)
Analysed with a follow-up of 6 months (n= 85)
Analysed with a follow-up of 1 year (n=82) Analysed with a follow-up of 1 year (n=85)
Figure 1. Consort ﬂow chart.
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changes in QoL caused by venous insufﬁciency, was used to analyse
the 2-week postoperative morbidity caused by the treatment. This
20-item questionnaire (CIVIQ2) provides a proﬁle on four QoLFigure 2. The tulip ﬁbre.dimensions (psychological, pain, physical and social) speciﬁc to
venous disorders in the lower limb. The CIVIQ2 has been demon-
strated to be a valid, reliable, stable and sensitive scale.12,13 The QoL
questionnaire had to be completed on the 14th postoperative day
and to be returned at the 1 month postoperative check-up.
In order to evaluate ecchymosis, we developed a scale in
which the postoperative ecchymosis around the ablated vein was
measured in square centimetres (cm2), and this measured
surface was divided by the length of the treated vein. Measure-
ment of ecchymosis was performed at the 5th postoperative day.
The patients fulﬁlled a visual analogue pain score (0e10) at the
ﬁrst clinical control (5th postoperative day). Another visual
analogue pain score was ﬁlled in to accompany the QoL ques-
tionnaire. This second VAS measured average pain intensity for
the ﬁrst 2 postoperative weeks. The patients’ satisfaction rate
was measured using a VAS (0e10) and included the written
questionnaire. Patients were blinded concerning which ﬁbre was
used and ﬁlled in the questionnaires in the absence of the
treating consultant.
Table 1
Patients characteristics.
Tulp ﬁbre Bare ﬁbre
n 87 87
Average age 51.41 (SD:13,4) 52.29 (SD:13,2) p ¼ 0.66
BMI 25.36 (SD:3.7) 26.81 (SD:5.06) p ¼ 0.038
Max diameter 7.4 mm (SD:2.7) 7.5 (SD:2.8) P ¼ 0.73
Mean diameter 5.7 mm (SD:1.8) 5.9 mm (SD:2.1) p ¼ 0.50
Length 36.3 cm (SD:8.4) 34.16 cm (SD:10.9) p ¼ 0.14
LEED 59.6 J/cm (SD:8.04) 63.4 J/cm (SD:9.92) p ¼ 0.007
Fluence 36 J/cm2(SD:10.3) 37.8 J/cm2 (SD:12.5) p ¼ 0.30
Gender (female) 78% 73% p ¼ 0.50
Student T-Test.
Table 2
Patients data.
Factor Bare Tulip Sig
25% Median 75% 25% Median 75%
Echymosis Score 0.08 0.21 0.66 0.00 0.04 0.14 0.000
Painscore d5- 1.00 2.00 3.50 0.00 1.00 2.00 0.000
Painscore 2 weeks 1.00 2.00 3.00 1.00 2.00 3.00 0.180
Analgetics, days 0.00 1.00 2.00 0.00 0.00 1.00 0.111
Analgetics, total number 0.00 1.00 2.50 0.00 0.00 2.00 0.119
QoL (0e100) 24 32 40 23 27 34 0.023
Satisfaction 9.00 10.00 10.00 8.00 9.50 10.00 0.564
Mann Whitney-U test.
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We used the Groupe d’ Évaluation des Lasers et de l’Échographie
Vasculaire (GELEV) score (Table 3) to interpret the occlusion rate. In
this score the diameter of the treated vein is compared to the
diameter measured in the preoperative duplex mapping.14 For this
purpose, we used the proximal measured diameter of the treated
vein, which is located 2 cm distal to the SFJ. This diameter was
compared at the various outpatient reviews, and the veins were
classiﬁed using the GELEV score. These duplex controls were
carried out by independent, blinded radiologists.
Data analyses were done by a study nurse and an independent
registrar.
Calculation of energy deposits
We use the term linear endovenous energy density (LEED)15 to
refer to the amount of energy in Joules divided by the treated vein
length in centimetres. The term endovenous ﬂuence (EF)8 is used to
describe the quotient of the energy in Joules delivered to the
approximated inner vessel surface (calculated using the mean diam-
eter of the three reference diameters measured preoperatively with
the patient in the standing position). The advantage of using EF is that
it makes it easy to compare energy used in treated veinswith various
diameters, since the diameter is included in the calculation ofﬂuence.
Statistical evaluation
Statistical analysis was performed using SPSS 19.0 (Statistical
Package for the Social Sciences). For correlation analysis, we used
the Spearman correlation test. Inter-group variances for unpaired
continuous and ordinal data (patient data) were evaluated non-
parametrically using the Student’s t-test. We used the Manne
Whitney U test to evaluate the clinical results. An a-level of
signiﬁcance of 0.05 was used. A linear regressionmodel was used to
correct the inﬂuence of a different patient parameter (LEED and
BMI) on the side effects. To compare the occlusion rates (primary
outcome factor), non-inferiority was investigated using New-
combe’s 95% CI for the difference of two independent proportions
(Altman et al., 2000). Calculations were based on the ‘scoreci’
function from the ‘PropsCIs’ library (Scherer, 2010) in R 2.14.1 (The R
Foundation for Statistical Computing, 2011).
Results
In total, 368 patients were assessed for treatment of an
incompetent GSV. One hundred and ﬁfty-three patients were
excluded according to the protocol. Another 41 patients refused to
be randomised.
The mean age was 51.4 years (SD: 13.3) and the female
predominance was 75.8%.
The CEAP classiﬁcation showed that the vast majority of the
treated veins were uncomplicated and there was no difference
between the two groups: 61 C2, 20 C3, 3 C4, 0 C5, 3 C6 (bare ﬁbre);
68 C2, 8 C3, 7 C4, 1 C5, 3 C6; the median was C2 for both.
The two patient cohorts were similar (Table 1) except for LEED
and BMI.
The average energy used in patients treated with a bare ﬁbre
was on average 63.4 J cm1 and 59.6 J cm1 in patients treated with
a tulip ﬁbre. This difference was statistically signiﬁcant (p ¼ 0.007).
Nevertheless, no statistically signiﬁcant difference could be found
when comparing the EF in the two groups (p ¼ 0.3). The average
BMI ﬁgures were 26.8 and 25.3 in the bare-ﬁbre group and the
tulip-ﬁbre group, respectively (p ¼ 0.04).
Postoperative ‘ecchymosis’ is mainly due to vein wall perfora-
tions. Patients treated with a bare ﬁbre had signiﬁcantly moreecchymosis compared to patients treated with a tulip ﬁbre (0.21 vs.
0.04, p < 0.001). These patients also had a signiﬁcantly higher pain
score measured on the 5th postoperative day (median 2.00 vs. 1.00,
p < 0.001). There was no difference in the average ‘pain’ during the
ﬁrst 2 postoperative weeks. Patients treated with a bare ﬁbre, as
compared to those treated with a tulip ﬁbre, needed somewhat
more ‘analgesics’ (number of tablets respectively: median 1.0 vs.
0.0, p ¼ 0.11) and for a longer period (respective median number of
days: 1.0 vs. 0.0; p ¼ 0.11) but this difference was not statistically
signiﬁcant (Table 2).
The QoL score (CIVIQ2 Questionnaire) allowed us to rate post-
operative morbidity (including pain) after EVLA. This postoperative
morbidity was signiﬁcantly lower in the group treated with a tulip
ﬁbre (p ¼ 0.023) (Table 2).
At the 1 month clinical check-up the ‘patient’ satisfaction rate’
was measured using a VAS (0e10). This was part of the question-
naire. The median scores were 9.5 and 10 for the tulip group and
the bare ﬁbre group, respectively. There was statistically no
signiﬁcant difference (p ¼ 0.56) between the two cohorts.
‘Ultrasound scans’ were performed at 1 month, 6 months and 1
year postoperatively.
At 1 month, 173 patients were checked (Fig. 1 Consort ﬂow
chart). At 6 months and 1 year respectively 168 and 167 patients
were checked. The ‘occlusion rates’ at 1 year were 96.4% and 98.7%
respectively for the veins treated with a bare ﬁbre and a tulip ﬁbre
(calculations based on the group of patients checked) (Table 3).
Some non-closed veins at 6 months postoperative closed sponta-
neously in the following months. A signiﬁcant degree of shrinkage
of the veins was noted. At 1 year for 89.4% (bare ﬁbre) and 85.3%
(tulip ﬁbre) of the patients checked, the vein had evolved into
a ﬁbrotic cord. We were unable to ﬁnd any signiﬁcant differences
between the two cohorts in terms of occlusion rate and vein
shrinkage.
At 1 year, new incompetence of the anterior accessory saphe-
nous vein (ASV) was noted in 12 patients (7.1%).
Discussion
Some of the side effects of EVLA can be explained by the use of
a bare ﬁbre. The direct contact between the ﬁbre tip and the vein
Table 3
Occlusion rates.
1 Month 6 Months 1 Year
Bare
ﬁbre
Tulip
ﬁbre
Bare
ﬁbre
Tulip
ﬁbre
Bare
ﬁbre
Tulip
ﬁbre
Lev 0 0 0 0 0 0 0
Lev 1a 0 2 0 1 2 0
Lev 1b 1 1 3 6 1 1
Lev 2a 56 50 2 2 0 0
Lev 2b 19 24 7 9 0 0
Lev 3 10 9 22 22 6 11
Lev 4 1 0 51 43 76 70
Not-controlled 0 1 2 4 2 5
Total 87 87 87 87 87 87
Occlusion rate 86/87
(98.8%)
83/86
(96.5%)
82/85
(96.4%)
76/83
(91.6%)
82/85
(96.4%)
81/82
(98.7%)
GELEV-score: Lev 0: no occlusion, reﬂuxing vein, unchanged vein. Lev 1a: partial
occlusion with proximal reﬂux. Lev 1b: partial occlusion without reﬂux. Lev 2a:
complete occlusion with unchanged or larger diameter. Lev 2b: complete occlusion
with diameter reduction >30%. Lev 3: complete occlusion with diameter reduction
>50%. Lev 4: ﬁbrotic cord, vein not visible.
This scoring was introduced by GELEV(Groupe d’ Évaluation des Lasers et de
l’Échographie Vasculaire, part of the “ Société Française d’Angéiologie”).
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perivenous tissue destruction can be noticed at this point of direct
contact.1,10 The use of a tulip ﬁbre avoids this direct contact since
the ﬁbre tip is centred intraluminally (Fig. 2). This results in
a more even energy distribution to the vein wall. Patients treated
with a bare ﬁbre did receive somewhat more energy than those
treated with a tulip ﬁbre (LEED respectively 63.4 J cm1 vs.
59.6 J cm1, p ¼ 0.007). A linear regression model was used to
model the mean of the measured ecchymosis, pain score and QoL
score to adjust for the differences in LEED. After this correction, it
was possible to prevent the energy difference inﬂuencing the
outcome factors.
Avoiding vein wall perforations clearly reduces the incidence of
ecchymosis. Less perivenous tissue destruction can minimise the
postoperative inﬂammatory reactions and pain. In fact, we also
found a strong correlation between the measured ecchymosis and
the postoperative pain score (VAS, 5th day) (Pearson correlation
r ¼ 0.274, p ¼ 0.000). The differences in side effects only encom-
passed the immediate postoperative period; the score for the
average pain during the 2 weeks postoperatively no longer showed
any difference.
In terms of occlusion rates wewere unable to ﬁnd any difference
between the patient cohorts (non-inferiority using Newcombe’s
95% CI, estimated difference: e2.3 [e8.7; 3.5 ]). At 6 months post-
operatively we found some cases of proximal recanalisation of the
treated veins (n ¼ 10, no signiﬁcant differences between the two
groups). We deﬁned a recanalisation as a vein with an open lumen
and intraluminal ﬂow at a distance of more than 2 cm distal to the
SFJ. These non-closed veins were mostly short proximal stumps
with a ﬁlliform lumen and a thickened vein wall. At the 1-year
check, however, most of these non-occluded veins had closed
spontaneously. This reopening and subsequent reclosing of treated
veins can be explained by the healing process: the inﬁltration of the
vein wall with necro-inﬂammatory tissue will lead to a ﬁbrotic
process resulting in shrinking of the vein and will end in a ﬁbrotic
cord if the thermal destruction has been sufﬁcient.1,10 The intra-
luminal thrombus, however, which causes the thrombotic occlu-
sion of the vein in the immediate postoperative period, resolves
during the postoperative period. If this thrombus dissolves more
quickly than the ﬁbrotic process closes the veins, especially at the
proximal end where the vein diameter is larger and nearer to the
central circulation, the result will be temporary recanalisation. All
those patients stayed asymptomatic. Later these proximal stumpswill continue to shrink and evolve into a ﬁbrotic cord.14,16e18 After 6
months postoperatively, no newly formed recanalisations could be
found.
At 1 year, respective occlusion rates were noted of 96.4% and
98.7% (bare ﬁbre vs. tulip ﬁbre). To interpret the occlusion rates, we
used the GELEV score (Table 3). This score makes it possible to
evaluate the morphological evolution of the treated veins. The
marked shrinkage of the treated veins due to ﬁbrotic organisation
can guarantee very good long-term results.
We did not, however, use the KaplaneMeier survival curve,
which is very often used in clinical trials, specially to look for
a speciﬁc event or end point (recanalisation in this trial).19 The
control intervals in this trial are too irregular and too long. If we
notice a recanalisation at 6months postoperatively, this ‘event’may
have happened several months previously.
Some of the recanalised veins also re-close spontaneously some
months later. This ‘new event’ cannot be included in a Kaplane
Meier life table.
The advantage of using a tulip ﬁbre is that by avoiding the direct
contact between the ﬁbre tip and the vein wall, some possible
adverse effects of EVLA could be avoided. This tulip ﬁbre was
previously tested in an animal model.1 EVLA using a tulip ﬁbre
avoids ulceration and perforation of the vein associated with
treatment using a bare ﬁbre. It also results in more even circum-
ferential vein wall necrosis and less pervious tissue destruction.
Other new laser ﬁbre designs are the NeverTouch VenaCure
laser ﬁbre (AngioDynamics, Queensbury, NY, USA) and the radial
ﬁbre (Cereals E, Biolitec). A retrospective chart review20 showed
a ﬁvefold increase in the failure rates (recanalisations) for vein
segments treated with EVLA using the NeverTouch gold-tip ﬁbre
compared with standard bare-tip ﬁbres. Promising results have
been published using the radial ﬁbre.21 EVLA of the GSV with
radially emitting laser ﬁbre by using a 1470-nm diode laser is safe
and efﬁcient. The cost of a radial ﬁbre is about double of a that of
a tulip ﬁbre. These prices can vary from country to country.
At 1 year postoperatively, we found cumulative newly formed
incompetence of the anterior accessory saphenous vein in 12
patients (7.1%). This incompetence may be the cause of a clinical
recurrence of varicose veins. One of the advantages of endovenous
thermal ablation techniques is the avoidance of a crossectomy. The
inguinal dissection and ligature of the SFJ and side branches can
induce neovascularisation, which is a common cause of recurrent
varicose veins after surgical treatment of saphenous vein
reﬂux.22,23 Neovascularisation can be seen more frequently,
although statistically not signiﬁcantly different, following cross-
ectomy/stripping as compared to endovenous thermal ablation.24
Since it has been shown that extended SFJ ligation may add little
to effective GSV obliteration, crossectomy is no longer performed.25
The occurrence of new incompetence of the ASV after EVLA may,
however, contribute to the discussion about the role of SFJ ligation
in the treatment of saphenous vein incompetence. Further clinical
trials are necessary to evaluate this new ASV incompetence on the
long-term clinical results of endovenous thermal techniques.Conclusion
Using a tulip ﬁbre for EVLA of the GSV results, as compared with
the use of a bare ﬁbre, in equal occlusion rates at 1 year post-
operatively, but in less postoperative ecchymosis and pain. Patients
treated with a tulip ﬁbre seem to have a better postoperative QoL.Funding
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